$RGLS
Regulus Therapeutics Inc. Stock $rgls

$rgls Overview Financials Valuation SEC Filings Company Website

2019 Q2 Form 10-Q Financial Statement

#000162828019006483 Filed on May 10, 2019

Income Statement

Concept	2019 Q2	2019 Q1	2018 Q1
Revenue	$18.00K	$6.778M	$18.00K
YoY Change	0.0%	37555.56%	0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.850M	$3.530M	$3.770M
YoY Change	-14.93%	-6.37%	-4.8%
% of Gross Profit
Research & Development	$1.836M	$5.983M	$11.83M
YoY Change	-81.66%	-49.42%	-24.91%
% of Gross Profit
Depreciation & Amortization	$170.0K	$502.0K	$563.0K
YoY Change	-69.64%	-10.83%	-19.46%
% of Gross Profit
Operating Expenses	$4.686M	$9.516M	$15.60M
YoY Change	-64.93%	-39.0%	-20.85%
Operating Profit	-$4.668M	-$2.738M	-$15.58M
YoY Change	-65.02%	-82.43%	-20.87%
Interest Expense	$538.0K	$578.0K	$605.0K
YoY Change	-13.37%	-4.46%	10.81%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$5.015M	-$3.260M	-$16.02M
YoY Change	-63.78%	-79.66%	-19.98%
Income Tax	$1.000K	$0.00	$1.000K
% Of Pretax Income
Net Earnings	-$5.016M	-$3.260M	-$16.03M
YoY Change	-63.78%	-79.66%	-19.96%
Net Earnings / Revenue	-27866.67%	-48.1%	-89027.78%
Basic Earnings Per Share
Diluted Earnings Per Share	-$300.4K	-$314.1K	-$1.849M
COMMON SHARES
Basic Shares Outstanding	20.55M shares	10.74M shares	104.0M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q2	2019 Q1	2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$19.60M	$10.30M	$45.10M
YoY Change	-40.43%	-77.16%	-21.57%
Cash & Equivalents	$19.57M	$10.32M	$10.06M
Short-Term Investments			$35.10M
Other Short-Term Assets	$556.0K	$801.0K	$1.451M
YoY Change	-63.8%	-44.8%	-58.94%
Inventory
Prepaid Expenses	$3.826M	$3.826M	$4.655M
Receivables	$300.0K	$2.800M	$200.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$24.28M	$17.74M	$51.43M
YoY Change	-38.1%	-65.51%	-23.98%
LONG-TERM ASSETS
Property, Plant & Equipment	$974.0K	$1.598M	$9.305M
YoY Change	-89.06%	-82.83%	-17.44%
Goodwill
YoY Change
Intangibles	$406.0K	$407.0K	$726.0K
YoY Change	-42.41%	-43.94%	-21.09%
Long-Term Investments
YoY Change
Other Assets	$27.00K	$133.0K	$620.0K
YoY Change	-91.77%	-78.55%	85.07%
Total Long-Term Assets	$1.407M	$2.138M	$10.65M
YoY Change	-85.84%	-79.93%	-14.96%
TOTAL ASSETS
Total Short-Term Assets	$24.28M	$17.74M	$51.43M
Total Long-Term Assets	$1.407M	$2.138M	$10.65M
Total Assets	$25.69M	$19.88M	$62.08M
YoY Change	-47.75%	-67.98%	-22.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.602M	$2.650M	$4.396M
YoY Change	-70.7%	-39.72%	-2.51%
Accrued Expenses	$1.152M	$1.745M	$3.371M
YoY Change	-44.88%	-48.23%	-28.12%
Deferred Revenue	$42.00K	$60.00K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$14.90M	$15.50M	$19.90M
YoY Change	-25.13%	-22.11%
Total Short-Term Liabilities	$20.49M	$24.84M	$30.93M
YoY Change	-33.48%	-19.7%	192.46%
LONG-TERM LIABILITIES
Long-Term Debt	$200.0K	$200.0K	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$461.0K	$1.106M	$438.0K
YoY Change	5.49%	152.51%	104.67%
Total Long-Term Liabilities	$461.0K	$1.106M	$438.0K
YoY Change	5.49%	152.51%	104.67%
TOTAL LIABILITIES
Total Short-Term Liabilities	$20.49M	$24.84M	$30.93M
Total Long-Term Liabilities	$461.0K	$1.106M	$438.0K
Total Liabilities	$20.95M	$25.95M	$39.20M
YoY Change	-45.92%	-33.82%	-5.41%
SHAREHOLDERS EQUITY
Retained Earnings	-$401.0M	-$396.0M	-$344.0M
YoY Change	7.25%	15.11%	17.02%
Common Stock	$405.7M	$389.9M	$383.0M
YoY Change	5.55%	1.79%	15.1%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.743M	-$6.069M	$22.88M
YoY Change
Total Liabilities & Shareholders Equity	$25.69M	$19.88M	$62.08M
YoY Change	-47.75%	-67.98%	-22.57%

Cashflow Statement

Concept	2019 Q2	2019 Q1	2018 Q1
OPERATING ACTIVITIES
Net Income	-$5.016M	-$3.260M	-$16.03M
YoY Change	-63.78%	-79.66%	-19.96%
Depreciation, Depletion And Amortization	$170.0K	$502.0K	$563.0K
YoY Change	-69.64%	-10.83%	-19.46%
Cash From Operating Activities	-$5.690M	-$4.433M	-$15.60M
YoY Change	-53.4%	-71.59%	-16.48%
INVESTING ACTIVITIES
Capital Expenditures			$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities	$110.0K	$160.0K	$11.44M
YoY Change	-99.3%	-98.6%	-38.16%
Cash From Investing Activities	$110.0K	$161.0K	$11.44M
YoY Change	-99.3%	-98.59%	-37.7%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$2.086M	$208.0K
YoY Change		902.88%	-21.51%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	14.83M	$657.0K	$701.0K
YoY Change	-21285.71%	-6.28%	161.57%
NET CHANGE
Cash From Operating Activities	-5.690M	-$4.433M	-$15.60M
Cash From Investing Activities	110.0K	$161.0K	$11.44M
Cash From Financing Activities	14.83M	$657.0K	$701.0K
Net Change In Cash	9.250M	-$3.615M	-$3.462M
YoY Change	169.68%	4.42%	6557.69%
FREE CASH FLOW
Cash From Operating Activities	-$5.690M	-$4.433M	-$15.60M
Capital Expenditures			$0.00
Free Cash Flow			-$15.60M
YoY Change			-17.09%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019Q1	dei	Amendment Flag AmendmentFlag	false
CY2019Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2019Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019Q1	dei	Document Period End Date DocumentPeriodEndDate	2019-03-31
CY2019Q1	dei	Document Type DocumentType	10-Q
CY2019Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001505512
CY2019Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	20548450	shares
CY2019Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2019Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2019Q1	dei	Entity Number Of Employees EntityNumberOfEmployees	21	employee
CY2019Q1	dei	Entity Registrant Name EntityRegistrantName	REGULUS THERAPEUTICS INC.
CY2019Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2019Q1	dei	Trading Symbol TradingSymbol	RGLS
CY2018Q1	rgls	Accumulated Other Comprehensive Income Loss Unrealized Gainon Short Term Investments AccumulatedOtherComprehensiveIncomeLossUnrealizedGainonShortTermInvestments	7000	USD
CY2019Q1	rgls	Cashand Cash Equivalentsand Marketable Securities CashandCashEquivalentsandMarketableSecurities	10300000	USD
CY2019Q1	rgls	Finance Lease Liability Payments Due Noncurrent FinanceLeaseLiabilityPaymentsDueNoncurrent	245000	USD
CY2019Q1	rgls	Finance Lease Liability Undiscounted Excess Amount Current FinanceLeaseLiabilityUndiscountedExcessAmountCurrent	287000	USD
CY2018Q1	rgls	Gainon Reductionof Lease Liability GainonReductionofLeaseLiability	0	USD
CY2019Q1	rgls	Gainon Reductionof Lease Liability GainonReductionofLeaseLiability	1317000	USD
CY2018Q1	rgls	Increase Decrease Operating Lease Liabilities IncreaseDecreaseOperatingLeaseLiabilities	0	USD
CY2019Q1	rgls	Increase Decrease Operating Lease Liabilities IncreaseDecreaseOperatingLeaseLiabilities	0	USD
CY2019Q1	rgls	Lease Liabilities LeaseLiabilities	532000	USD
CY2019Q1	rgls	Lease Payments Eliminated LeasePaymentsEliminated	14400000	USD
CY2019Q1	rgls	Lease Right Of Use Asset LeaseRightOfUseAsset	603000	USD
CY2019Q1	rgls	Noncash Gain Dueto Reductionof Lease Liability NoncashGainDuetoReductionofLeaseLiability	1300000	USD
CY2019Q1	rgls	Noncash Leasehold Improvements NoncashLeaseholdImprovements	5600000	USD
CY2019Q1	rgls	Operatingand Finance Lease Payments OperatingandFinanceLeasePayments	723000	USD
CY2018Q1	rgls	Payments For Finance Leases PaymentsForFinanceLeases	0	USD
CY2019Q1	rgls	Payments For Finance Leases PaymentsForFinanceLeases	65000	USD
CY2018Q1	rgls	Proceeds From Capital Lease Financing ProceedsFromCapitalLeaseFinancing	492000	USD
CY2019Q1	rgls	Proceeds From Capital Lease Financing ProceedsFromCapitalLeaseFinancing	0	USD
CY2018Q4	rgls	Rent Less Current Portion Liability RentLessCurrentPortionLiability	6820000	USD
CY2019Q1	rgls	Rent Less Current Portion Liability RentLessCurrentPortionLiability	0	USD
CY2016Q4	rgls	Tenant Improvement Allowance TenantImprovementAllowance	8200000	USD
CY2018Q4	rgls	Upfront Payment Received UpfrontPaymentReceived	2500000	USD
CY2019Q1	rgls	Upfront Payment Received UpfrontPaymentReceived	1800000	USD
CY2018Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	26000	USD
CY2019Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	2792000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1714000	USD
CY2019Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2650000	USD
CY2018Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-47000	USD
CY2019Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1625000	USD
CY2019Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1745000	USD
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	386860000	USD
CY2019Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	389903000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1627000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	959000	USD
CY2018Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1627000	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	959000	USD
CY2018Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	672310	shares
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
CY2018Q4	us-gaap	Assets Assets	27927000	USD
CY2019Q1	us-gaap	Assets Assets	19877000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	19295000	USD
CY2019Q1	us-gaap	Assets Current AssetsCurrent	17739000	USD
CY2018Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	11173000	USD
CY2019Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	8228000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13519000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10057000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13935000	USD
CY2019Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10320000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-3462000	USD
CY2019Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-3615000	USD
CY2019Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	1651000	shares
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2019Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8818019	shares
CY2019Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10817916	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8818019	shares
CY2019Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10817916	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	9000	USD
CY2019Q1	us-gaap	Common Stock Value CommonStockValue	11000	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16018000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3260000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2572000	USD
CY2019Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	60000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	6000	USD
CY2019Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0	USD
CY2018Q1	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	1843000	USD
CY2018Q4	us-gaap	Debt Current DebtCurrent	16575000	USD
CY2019Q1	us-gaap	Debt Current DebtCurrent	15225000	USD
CY2019Q1	us-gaap	Deferred Costs Leasing Accumulated Amortization DeferredCostsLeasingAccumulatedAmortization	900000	USD
CY2018Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	563000	USD
CY2019Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	502000	USD
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.85
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.31
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1601000	USD
CY2019Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1915000	USD
CY2019Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	6000	USD
CY2019Q1	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	7000	USD
CY2019Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	532000	USD
CY2019Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	600000	USD
CY2019Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	245000	USD
CY2019Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	287000	USD
CY2019Q1	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	559000	USD
CY2019Q1	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	57000	USD
CY2019Q1	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	287000	USD
CY2019Q1	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	215000	USD
CY2019Q1	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	27000	USD
CY2019Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	65000	USD
CY2019Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	603000	USD
CY2019Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	600000	USD
CY2019Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	46000	USD
CY2019Q1	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.049
CY2019Q1	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y
CY2019Q1	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	-1600000	USD
CY2018Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3773000	USD
CY2019Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3533000	USD
CY2015Q3	us-gaap	Incentive From Lessor IncentiveFromLessor	1400000	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16024000	USD
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3260000	USD
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2018Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	1000	USD
CY2019Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-185000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	2766000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1347000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	936000	USD
CY2018Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	377000	USD
CY2019Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	120000	USD
CY2018Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-18000	USD
CY2019Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2518000	USD
CY2018Q1	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-300000	USD
CY2019Q1	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	0	USD
CY2018Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-868000	USD
CY2019Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	314000	USD
CY2018Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-26000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-532000	USD
CY2018Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-90000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1076000	USD
CY2018Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-128000	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-368000	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	500000	USD
CY2019Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	407000	USD
CY2018Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	164000	USD
CY2019Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	56000	USD
CY2018Q1	us-gaap	Interest Expense InterestExpense	605000	USD
CY2019Q1	us-gaap	Interest Expense InterestExpense	578000	USD
CY2018Q1	us-gaap	Interest Paid InterestPaid	506000	USD
CY2019Q1	us-gaap	Interest Paid InterestPaid	437000	USD
CY2019Q1	us-gaap	Lease Cost LeaseCost	378000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4800000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27927000	USD
CY2019Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	19877000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	26646000	USD
CY2019Q1	us-gaap	Liabilities Current LiabilitiesCurrent	24840000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	701000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	657000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	11439000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4800000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	600000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1200000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1200000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1200000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	600000	USD
CY2015Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P96M
CY2019Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P51M
CY2018Q4	us-gaap	Liabilities Liabilities	33781000	USD
CY2019Q1	us-gaap	Liabilities Liabilities	25946000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	161000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15602000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4433000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-16025000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-3260000	USD
CY2015Q3	us-gaap	Net Rentable Area NetRentableArea	59248	sqft
CY2019Q1	us-gaap	Net Rentable Area NetRentableArea	24562	sqft
CY2018Q1	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	191000	USD
CY2019Q1	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	0	USD
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	15601000	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	9516000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-15583000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2738000	USD
CY2019Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	326000	USD
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	11300000	USD
CY2019Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	USD
CY2019Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2019Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	651000	USD
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	USD
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3300000	USD
CY2019Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.000
CY2019Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y
CY2018Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1140000	USD
CY2019Q1	us-gaap	Other Assets Current OtherAssetsCurrent	801000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	326000	USD
CY2019Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	133000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	7000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2018Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2559000	USD
CY2019Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3245000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	309000	USD
CY2019Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1106000	USD
CY2018Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	93000	USD
CY2019Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	139000	USD
CY2018Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4194000	USD
CY2019Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	3826000	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	208000	USD
CY2019Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2086000	USD
CY2018Q1	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	11439000	USD
CY2019Q1	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	0	USD
CY2018Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2019Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	161000	USD
CY2018Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1000	USD
CY2019Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7806000	USD
CY2019Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1598000	USD
CY2018Q1	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	0	USD
CY2019Q1	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	1364000	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11828000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5983000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-392723000	USD
CY2019Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-395983000	USD
CY2018Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6778000	USD
CY2019Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1627000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	959000	USD
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	390000	shares
CY2018Q4	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	603058	shares
CY2018Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	207000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2084000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	35216000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	22876000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-5854000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	-6069000	USD
CY2018Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.0833
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	8668695	shares
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10379830	shares
CY2019Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our condensed financial statements are prepared in accordance with GAAP, which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. An estimated loss contingency is accrued in our financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-19-006483-index-headers.html	Edgar Link	pending
0001628280-19-006483-index.html	Edgar Link	pending
0001628280-19-006483.txt	Edgar Link	pending
0001628280-19-006483-xbrl.zip	Edgar Link	pending
ex-101x20190331.htm	Edgar Link	pending
ex-107x20190331.htm	Edgar Link	pending
ex-311x20190331.htm	Edgar Link	pending
ex-312x20190331.htm	Edgar Link	pending
ex-321x20190331.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
rgls-20190331.xml	Edgar Link	completed
rgls-20190331.xsd	Edgar Link	pending
rgls-20190331_cal.xml	Edgar Link	unprocessable
rgls-20190331_def.xml	Edgar Link	unprocessable
rgls-20190331_lab.xml	Edgar Link	unprocessable
rgls-20190331_pre.xml	Edgar Link	unprocessable
rgls20190331-10q.htm	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RGLS
Regulus Therapeutics Inc. Stock $rgls

2019 Q2 Form 10-Q Financial Statement

#000162828019006483 Filed on May 10, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGLS Regulus Therapeutics Inc. Stock $rgls

2019 Q2 Form 10-Q Financial Statement

#000162828019006483 Filed on May 10, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGLS
Regulus Therapeutics Inc. Stock $rgls